Table 1.
Baseline characteristics of patients enrolled (n = 45)
| Category | Cohort N, (%) |
|---|---|
| Age (median, range) | 53 (35–79) |
| Sex | |
| Male | 19 (42.2) |
| Female | 26 (57.8) |
| Tumor origin | |
| Cutaneous | 15 (33.3) |
| Other | 30 (66.7) |
| Number of metastatic organs | |
| ≤ 2 | 32 (71.1) |
| > 2 | 13 (28.9) |
| Number of intrahepatic metastases | |
| ≤ 3 | 10 (22.2) |
| > 3 | 35 (77.8) |
| Diameter of the intrahepatic lesion (mm) | |
| ≤ 30 | 26 (57.8) |
| > 30 | 19 (42.2) |
| LDH level | |
| ≤ 300 U/L | 30 (66.7) |
| > 300 U/L | 15 (33.3) |
| Combined anti-PD-1 antibody | |
| Toripalimab | 18 (40.0) |
| Pembrolizumab | 27 (60.0) |
| Previous PD-1 blockade therapy | |
| Absent | 24 (53.3) |
| Present | 21 (46.7) |
| Chemotherapy | |
| Absent | 39 (86.7) |
| Present | 6 (13.3) |
| Anti-angiogenic agents | |
| Absent | 37 (82.2) |
| Present | 8 (17.8) |
| BRAF V600E/K mutation | |
| Absent or unknown | 42 (93.3) |
| Present | 3 (6.7) |